Low-grade gliomas are among the most common primary brain tumors in childhood and can affect patients for life, which is why early diagnosis involving the tumor microenvironment is of significant importance. An international study published in 2025, in which the researchers used imaging mass cytometry to examine over 100 tumor samples at the single-cell level, revealed new therapeutic approaches with the potential combination of blocking the immune checkpoint receptor TIM-3 expressed on myeloid cells with inhibition of the MAPK signaling pathway.
Autoren
- Dr. oec. Odile Schwarz-Herion
Publikation
- InFo ONKOLOGIE & HÄMATOLOGIE
Related Topics
You May Also Like
- Ulcerative colitis
Rgs14 protein can worsen the severity
- Mastocytosis
Innovative pathogenesis-based therapeutic approaches in the pipeline
- Participation of the patient
Adherence in psychiatry
- Psychooncology
Communication as the key to therapy adherence
- From symptom to diagnosis
Renal cell carcinoma
- Lipid management: ESC/EAS guideline update 2025
New recommendations on CVD risk classification, lipid lowering in statin intolerance and hoFH
- Chronically active MS lesions
New paradigm in the diagnosis and treatment of multiple sclerosis
- AI in neurology